BACKGROUND: Deletions of the long arm of chromosome 11 are frequently identified in human neuroblastomas. PROCEDURE: We screened 394 primary neuroblastomas and 52 tumor-derived cell lines with a panel of 11q and 11p polymorphic markers to determine the frequency of chromosome 11 allelic deletion, and to differentiate partial deletions of chromosome 11q (unb[11q] LOH) from whole chromosome loss. RESULTS: Allelic deletion occurred most frequently at cytogenetic band 11q23 and was detected in 161 primary neuroblastomas (41%) and 18 cell lines (35%). Eighty-seven tumors (22%) had unb[11q] LOH with a heterogeneous distribution of deletion breakpoints. Unb[11q] LOH was highly correlated with age > 1 year at diagnosis (P = 0.008), stage 4 disease (P = 0.001), unfavorable Shimada histopathology (P < 0.001), and assignment to a high-risk therapeutic protocol (P < 0.001), and was inversely correlated with MYCN amplification (P = 0.018). Patients whose tumors showed unb[11q] LOH were less likely to survive (P < 0.001), but there was only a trend towards an independent prognostic influence in multivariate analyses. CONCLUSIONS: Thus, structural rearrangements resulting in unb[11q] LOH commonly occur during the malignant evolution of high-risk neuroblastomas with single-copy MYCN. Copyright 2000 Wiley-Liss, Inc.
BACKGROUND: Deletions of the long arm of chromosome 11 are frequently identified in humanneuroblastomas. PROCEDURE: We screened 394 primary neuroblastomas and 52 tumor-derived cell lines with a panel of 11q and 11p polymorphic markers to determine the frequency of chromosome 11 allelic deletion, and to differentiate partial deletions of chromosome 11q (unb[11q] LOH) from whole chromosome loss. RESULTS: Allelic deletion occurred most frequently at cytogenetic band 11q23 and was detected in 161 primary neuroblastomas (41%) and 18 cell lines (35%). Eighty-seven tumors (22%) had unb[11q] LOH with a heterogeneous distribution of deletion breakpoints. Unb[11q] LOH was highly correlated with age > 1 year at diagnosis (P = 0.008), stage 4 disease (P = 0.001), unfavorable Shimada histopathology (P < 0.001), and assignment to a high-risk therapeutic protocol (P < 0.001), and was inversely correlated with MYCN amplification (P = 0.018). Patients whose tumors showed unb[11q] LOH were less likely to survive (P < 0.001), but there was only a trend towards an independent prognostic influence in multivariate analyses. CONCLUSIONS: Thus, structural rearrangements resulting in unb[11q] LOH commonly occur during the malignant evolution of high-risk neuroblastomas with single-copy MYCN. Copyright 2000 Wiley-Liss, Inc.
Authors: Marta Jeison; Shifra Ash; Gili Halevy-Berko; Jacques Mardoukh; Drorit Luria; Smadar Avigad; Galina Feinberg-Gorenshtein; Yacov Goshen; Gabriel Hertzel; Joseph Kapelushnik; Ayelet Ben Barak; Dina Attias; Ran Steinberg; Jerry Stein; Batia Stark; Isaac Yaniv Journal: Am J Pathol Date: 2010-04-15 Impact factor: 4.307
Authors: John M Maris; George Hii; Craig A Gelfand; Shobha Varde; Peter S White; Eric Rappaport; Saul Surrey; Paolo Fortina Journal: Genome Res Date: 2005-08 Impact factor: 9.043
Authors: Shahab Asgharzadeh; Jill A Salo; Lingyun Ji; André Oberthuer; Matthias Fischer; Frank Berthold; Michael Hadjidaniel; Cathy Wei-Yao Liu; Leonid S Metelitsa; Roger Pique-Regi; Peter Wakamatsu; Judith G Villablanca; Susan G Kreissman; Katherine K Matthay; Hiroyuki Shimada; Wendy B London; Richard Sposto; Robert C Seeger Journal: J Clin Oncol Date: 2012-08-27 Impact factor: 44.544
Authors: Katleen De Preter; Jo Vandesompele; Björn Menten; Philippa Carr; Heike Fiegler; Anders Edsjö; Nigel P Carter; Nurten Yigit; Wim Waelput; Nadine Van Roy; Scott Bader; Sven Påhlman; Frank Speleman Journal: BMC Genomics Date: 2005-07-06 Impact factor: 3.969
Authors: M E Luttikhuis; J E Powell; S A Rees; T Genus; S Chughtai; P Ramani; J R Mann; C M McConville Journal: Br J Cancer Date: 2001-08-17 Impact factor: 7.640
Authors: Katleen De Preter; Jo Vandesompele; Jasmien Hoebeeck; Caroline Vandenbroecke; Jöel Smet; Annick Nuyts; Geneviève Laureys; Valérie Combaret; Nadine Van Roy; Frank Roels; Rudy Van Coster; Marleen Praet; Anne De Paepe; Frank Speleman Journal: BMC Cancer Date: 2004-08-24 Impact factor: 4.430